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Transcription factorThe heart adapts to an increased workload through the activation of a hypertrophic response within the
cardiac ventricles. This response is characterized by both an increase in the size of the individual
cardiomyocytes and an induction of a panel of genes normally expressed in the embryonic and neonatal
ventricle, such as atrial natriuretic peptide (ANP). ANP and brain natriuretic peptide (BNP) exert their
biological actions through activation of the natriuretic peptide receptor-1 (Npr1). The current study
examined mice lacking Npr1 (Npr1−/−) activity and investigated the effects of the absence of Npr1
signaling during cardiac development on embryo viability, cardiac structure and gene and protein
expression. Npr1−/−embryos were collected at embryonic day (ED) 12.5, 15.5 and neonatal day 1 (ND 1).
Npr1−/−embryos occurred at the expected Mendelian frequency at ED 12.5, but knockout numbers were
signiﬁcantly decreased at ED 15.5 and ND 1. There was no indication of cardiac structural abnormalities
in surviving embryos. However, Npr1−/−embryos exhibited cardiac enlargement (without ﬁbrosis) from
ED 15.5 as well as signiﬁcantly increased ANP mRNA and protein expression compared to wild-type
(WT) mice, but no concomitant increase in expression of the hypertrophy-related transcription factors,
Mef2A, Mef2C, GATA-4, GATA-6 or serum response factor (SRF). However, there was a signiﬁcant
decrease in Connexin-43 (Cx43) gene and protein expression at mid-gestation in Npr1−/−embryos. Our
ﬁndings suggest that the mechanism by which natriuretic peptide signaling inﬂuences cardiac
development in Npr1−/− mice is distinct from that seen during the development of pathological cardiac
hypertrophy and ﬁbrosis. The decreased viability of Npr1−/−embryos may result from a combination of
cardiomegaly and dysregulated Cx43 protein affecting cardiac contractility.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) regulate blood pressure by vasodilation, by increasing vascular
permeability resulting in a net movement of ﬂuid out of the vascular
compartment and by modulating the rate of diuresis and natriuresis
through the kidneys [1,2]. During development the natriuretic peptide
system is functional by mid-gestation, and is capable of responding to
volume stimuli, regulating blood pressure and salt and water balance
in the developing embryo [3,4]. Circulating levels of ANP have been
shown to be higher in the fetus than in adults, and fetal ventricles
express higher levels of both ANP and BNP than adult ventricles [5,6].
Both ANP and BNP are expressed within the myocardium from ED 8.0
and are two of the ﬁrst markers of heart formation [7,8]. After birth,
ANP is down regulated in the ventricles, and in the adult expression in64 3 364 0525.
t).
ll rights reserved.the atria is 1000-fold higher than in the ventricles. Re-activated
ventricular ANP expression occurs in response to cardiac stress and
serves as the most highly conserved marker of hypertrophy [9]. In
association with the reappearance of ANP expression in the adult
ventricle, cardiac contractile protein genes, normally only active
during cardiac development, are also re-expressed leading to the
identiﬁcation of the embryonic gene program characteristic of
pathological ventricular hypertrophy [10,11].
Transgenic mouse models lacking the natriuretic peptide receptor
(NPR)-A gene (Npr1−/−) have been widely used to illustrate the
essential role of natriuretic peptide signaling in suppressing the
development of cardiac hypertrophy and ﬁbrosis on cardiac function
and survival [12–16]. These studies have focused on the effect of
disrupted natriuretic peptide signalling in adult animals only. Further
investigations utilizing these and other animal models have charac-
terized the molecular mechanisms by which natriuretic peptide
signaling mediates the hypertrophic response in a variety of
pathological states [16–19].
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suggest the natriuretic peptide system in the fetal heart and circulation
may regulate both physiological ﬂuid balance and cellular develop-
ment within cardiomyocytes [20]. Both immune and non-immune
fetal hydrops are associated with higher than normal fetal concentra-
tions of circulating ANP [21], while fetal cardiac distress is associated
with increased BNP expression reminiscent of heart failure in the adult
[22]. Despite this, few studies have investigated natriuretic peptide
signaling during the process of heart development itself.
A large number of studies have identiﬁed the critical role of
natriuretic peptide signaling in the development of pathological
hypertrophy in adults. In this study we tested the hypothesis that
ablation of Npr1 signaling during cardiac development would result in
the early establishment of a hypertrophic phenotype. The aim of this
study was to determine if gene and protein expression during cardiac
development in Npr1−/− mice was characteristic of pathological or
physiological cardiac hypertrophy.
2. Materials and methods
2.1. Generation and genotyping of mice
Npr1−/−mice and WT controls were generated as previously des-
cribed [12]. Experiments were performed according to the protocols
approved by the Animal Ethics Committee of the University of Otago.
Male and female Npr1−/− and WT embryos from timed matings
between Npr1+/− dams and Npr1−/− sires and WT dams and sires
were collected at ED 12.5 and 15.5 and neonatal pups collected at ND1.
Npr1−/− damswere not used for breeding in this study due to reduced
conception rates, poor maternal behaviour and increased rates of
infanticide in the few successful pregnancies observed. Npr1−/−
embryos and ND 1 pups from these matings were not used in the
current study. Embryos were collected after sacriﬁcing the pregnant
dams by cervical dislocation following Halothane BP™ (Nicolas
Piramal I Ltd, London) anesthesia. Embryos were rapidly dissected
out of the uterine horns and separated from the placenta in ice-cold,
RNase-free, phosphate buffered saline solution. Embryos were
digitally photographed against a grid and ruler to assess body
dimensions. The embryonic left hind limb was removed for DNA
extraction and the embryos immersion-ﬁxed in 10% neutral buffered
formalin. ND 1 pups were sacriﬁced by rapid decapitation, tails
removed for DNA extraction and whole bodies immersion-ﬁxed as
above. Genomic DNAwas extracted via a standard phenol–chloroform
extraction protocol from embryonic left hind limbs or tail-tips of ND 1
mice and genotyped as previously described [12,23].
Systolic and diastolic blood pressures in conscious dams were
measured by a non-invasive, computerized tail–cuff system (ADIn-
struments, Dunedin, New Zealand) as previously described [23]. The
mice were familiarized to the procedure by being placed in the
restrainer and the tail cuff system for a period of 7 days, after which
baseline mean arterial pressure (MAP) measurements were made for
each animal (mean of at least ten recordings), and repeated at 10 and
15 days post coitum (dpc) or until sacriﬁce.
2.2. Gender determination of collected embryos
To determine the gender of embryos a PCR-based assay was
established utilizing a variant of the structural maintenance of
chromosomes (SMC) gene located on the X-chromosome (accession
number AC083816), which has a Y-chromosome homolog containing
a 30-bp intronic deletion. The region of the gene surrounding the
deletion site was ampliﬁed, using the following primers (forward 5′
CCGCTGCCAAATTCTTTGG and reverse 5′CTCAAAAGCCAAAAGCTTCA).
Ampliﬁcation of the X-chromosomal SMC variant produced a 330-bp
fragment and the Y-chromosomal variant, produced a 300-bp
fragment visualized by gel electrophoresis.2.3. Histological characterization of Npr1−/− and WT embryos
Before being sectioned, embryos and ND 1 pups were either
transferred to 10% neutral-buffered formalin containing 10% sucrose
as a cryoprotectant for 24 h and then embedded in OCT medium
(Miles; Elkhart, IN, n=6 per gender and genotype at each gestational
age), or parafﬁn embedded (n= 6 per gender and genotype at each
gestational age). An equal number of embryos and neonates per group
were embedded such that the heart could be sectioned in either the
transverse or sagittal plane. The use of two anatomical planes ensured
that cardiac morphology could be thoroughly examined, especially
the locations of the great vessels and the structures of the
interventricular and interatrial septa. Histological analysis was
performed on 20-μm-thick serial cryostat sections and 3-μm-thick
serial parafﬁn sections (Leica Microsystems), stained with either
hematoxylin and eosin (H&E) or Masson's trichrome and examined
under bright-ﬁeld illumination (Olympus BX50). Composite photo
images of the entire heart structure were compiled using Photoshop
Elements 4.0 (Adobe Systems Inc.). Heart size for each embryo, as well
as individual chamber dimensions, ventricular septal length and
width, and free wall thickness in each chamber were determined on
transverse sections under light microscopy with an eyepiece graticule
(Olympus Model WH10X3) using a modiﬁed Cavalieri method [24].
ED 12.5 and 15.5 hearts were viewed at a total magniﬁcation of 100×,
while ND 1 hearts were viewed at a total magniﬁcation of 40×.
Additionally, the number of nuclei per photographic ﬁeld was
recorded within representative regions of the free wall of the mid
left ventricle (LV) at 400× magniﬁcation. In all cases the mean of ﬁve
independent sections per specimen was used for statistical analysis.
2.4. RNA isolation and quantitative real-time PCR analysis
Total RNA was isolated from whole ED 12.5 and 15.5 embryos and
excised hearts (atria and ventricles combined) of ND 1 as described
previously (n= 6 per gender and genotype at each gestational age)
[23]. Brieﬂy tissues were homogenized in a Retsch MM301 tissue mill
at 30 Hz for 10min in 800 μl pre-chilled TRIzol™ (Invitrogen, Carlsbad,
CA). Chloroform (160 μl) was added and samples were centrifuged at
12,000 g for 15 min at room temperature. The RNA-containing
supernatant was puriﬁed by RNeasyMidi andMini columns according
to manufacturer's instructions (Qiagen, Hilden, Germany).
Quantitative real-time PCR (RT-PCR) analysis was performed on
cDNA generated from 2.5 μg of total RNA as previously described [23].
Oligonucleotide primer sequences and PCR annealing temperatures
are given in Table 1. PCR reactionswere performed in a total volume of
30 μl containing 1 μl cDNA, 0.4 mM primers, 1× PCR buffer, 0.2 mM
dNTPs, 1.5 mMMgCl2, 10 nM Sybr Green 1 (Roche, IN) and 1U TAQ-Ti
DNA polymerase (Fisher Biotec, Australia). The PCR reaction condi-
tions were optimized for each gene of interest, and PCR products were
conﬁrmed by sequencing on an ABI 3100-Avant Genetic Analyzer
(Foster City, CA). Levels of mRNA expression were evaluated by
quantitative RT-PCR in either a Rotor-Gene RG-3000 real-time PCR
machine (Corbett Research, Australia) or a Light Cycler 480 (Roche
Diagnostics, IN) as previously described [23]. For each assay a hotstart
at 96 °Cwas performed for 2min followed by 30 cycles of denaturation
at 94 °C for 30 s, annealing for 35 s at the gene-speciﬁc annealing
temperature (Table 1) and extension at 72 °C for 30 s, after which a
melt curve was performed. Each sample was assayed in duplicate and
gene expression levels were quantiﬁed against a standard curve and
expressed as amount of message per μg of total RNA.
2.5. Immunohistochemistry
Npr1−/− andWTmice were collected at ED 12.5 and 15.5 and ND1
(n= 6 per gender and genotype at each gestational age), ﬁxed in 10%
formalin overnight at 4 °C followed by ethanol dehydration and
Table 1
Primer sequences and annealing temperatures for RT-PCR assays.
mRNA Primers Annealing
temperature
Angiotensin converting enzyme fwd TGCCTCCCAAGGAATTAGAA
rev CCATGCCCATAGCAATTCTT
59 °C
Angiotensinogen fwd AAGACCTCCCCTGTGAATGA
rev CCTGCCTCATTCAGCATCTT
65 °C
Angiotensin type 1 receptor fwd GGAAACAGCTTGGTGGTGAT
rev ACATAGGTGATTGCCGAAGG
63 °C
ANP fwd GAACCTGCTAGACCACCT
rev CCTAGTCCACTCTGGGCT
56 °C
BNP fwd AAGCTGCTGGAGCTGATAAGA
rev GTTACAGCCCAAACGACTGAC
56 °C
Connexin 43 fwd AACAGTCTGCCTTTCGCTGT
rev GGGCACAGACACGAATATGA
58 °C
GATA-4 fwd AATGCCTGTGGCCTCTATCA
rev CTGGTTTGAATCCCCTCCTT
58 °C
GATA-6 fwd AAGATGAATGGCCTCAGCAG
rev CATATAGAGCCCGCAAGCAT
56 °C
Mef2A fwd ACTCAAGGGCCTCTCCAAAT
rev CTTGATGGGGGAATGACAAC
54 °C
Mef2C fwd ATTTGGGAACTGAGCTGTGC
rev CGCTCATCCATTATCCTCGT
56 °C
Serum response factor Fwd GAGATTCTGGGATTGCTCCA
rev CAACAACCCTAGAGGGCAAA
58 °C
Sequences are listed 5′ to 3′. Forward primers are designated by fwd and reverse
primers by rev.
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cate using indirect immunoperoxidase staining (Envision®+ Dual
Link System-HRP, DakoCytomation, CA), on 3 μm serial sections on
poly-L-lysine coated slides.
Primary antibodies used for immunohistochemistry included, GATA-
4, Mef2, SRF from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) andFig. 1. Npr1 genotype distribution at weaning (A) and during gestation (B) and maternal blo
Npr1−/−, Npr1+/− and WT groups respectively. Signiﬁcant differences between the genoty
calculated from n= 8 per group, except for Npr1−/− where n= 4.Cx43 (Zymed laboratories, San Francisco, CA). ANP antiserum was a
generous gift from Associate Professor Tim Yandle (Endolab, University
of Otago-Christchurch). ANP antiserum was raised in New Zealand
white rabbits injected andboosted atmonthly intervalswith ratANP(3–
28) conjugated to bovine thyroglobulin followed by boosting with
human ANP (1–28) conjugated to bovine thyroglobulin. The ANP
antiserum exhibited high cross-reactivity to human, rat andmouse ANP
(N95%), but b5% cross-reactivity to other natriuretic peptides.
Brieﬂy, immunohistochemistry involved deparafﬁnized sections
being heat-treated for 2 min in citrate buffer (pH 6.0), quenching of
endogenous peroxidase activity with 3% hydrogen peroxidase in
distilledwater (15min at room temperature) andnon-speciﬁc binding
of IgG suppressed with 1% normal goat serum in phosphate buffered
saline (15 min at room temperature). The sections were incubated
with the primary antisera diluted to working concentrations of 1:300
for ANP, Cx43, Mef2 and GATA-4 and 1:500 for SRF at room
temperature for 1 h then visualized using liquid DAB+ (DakoCytoma-
tion, CA). Sections were counter-stained with alum hematoxylin.
Negative controls were obtained by omission of the primary antibody.
Representative antibody staining within the left ventricular free
wall and left atria was photographed for semi-quantitative densi-
tometry of DAB+ staining using light microscopy under bright-ﬁeld
illumination (Olympus BX50 microscope) and Leica digital camera,
DFC420. Intensity of DAB+ staining was determined using Meta-
Morph™ image analysis software (v6.2.6, Molecular Devices), as
previously described [25,26].
2.6. Statistical analysis
All results are expressed as means±SEM. The effects of genotype
(Npr1−/− vs. WT), gender and gestational age were tested by three-
way factorial ANOVA. Subsequent comparisons between genotypes atod pressure changes during gestation (C). Black, dark grey and light grey bars represent
pes are indicated by ⁎pb0.05, ⁎⁎pb0.01 and †pb0.001. Maternal blood pressures were
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relationships between expression levels for all genes and proteins
were tested with Pearson's correlation. All statistical analyses were
performed using SPSS version 11 (SPSS Inc., Chicago, IL). A p value of
b0.05 was considered signiﬁcant.
3. Results
3.1. Colony genotype distribution
The genotype distributions at weaning (approximately 4 weeks
after birth), identiﬁed that within this colony genotype distribu-
tions were non-Mendelian, with signiﬁcantly fewer than expected
Npr1−/− mice surviving to 4 weeks of age (Fig. 1A, 17% Npr1−/−,
58% Npr1+/− and 25% WT mice respectively, n= 250, p=0.009).
Litter sizes were comparable between WT and Npr1+/− dams
collected at ED 12.5 (Npr1+/− 5.1±0.8 vs. WT 6.3±1.1), at ED 15.5
(Npr1+/− 5.9±0.5 vs. WT 6.2±0.7) and at ND 1 (Npr1+/− 5.3±0.5Fig. 2. Representative digital photographs of male mice at EDs 12.5 and 15.5 (A), comparati
plane, ED 15.5 and ND 1 hearts in the coronal plane (B), and Masson's trichrome stained pa
from a 6-month-old Npr1−/− mouse, on the left a section through the LV wall and on the r
stained sections from ED 12.5 Npr1−/− andWTmice. Rows 3–5 are representative Masson's
labeled: A=right atria; RV= right ventricle; LV=left ventricle; white arrow indicates thevs. WT 5.6±0.6, n= 332 from 59 litters). The effect of genotype on
gestational survival, genotype distribution during embryogenesis was
studied in embryos collected from Npr1+/−/Npr1−/− timed matings
(Fig. 1B). At ED 12.5 the numbers of Npr1−/− embryos and Npr1+/−
embryos were approximately equivalent, as expected from heterozy-
gote-knockout matings (45% Npr1+/− and 55% Npr1−/−). By ED 15.5
the proportion of Npr1−/− embryos had declined to 39%. At ND 1 the
number of Npr1−/− mice was further reduced, with only 34% of the
collected embryos identiﬁed as Npr1−/−, instead of the expected 50%
(n=130, pb0.05).
3.2. Maternal blood pressure during pregnancy
Blood pressure was monitored throughout pregnancy in Npr1−/−,
Npr1+/− andWT dams. At baseline, mean arterial pressure (MAP, Fig.
1C) was signiﬁcantly different between genotypes, with the average
MAP of WT dams being 121 mm Hg compared to either Npr1+/− or
Npr1−/− (139 and 162 mm Hg, respectively, pb0.05). The MAP in allve composite H&E stained hearts of Npr1−/− and WT mice at ED 12.5 in the transverse
rafﬁn sections from the left ventricle (C). The top row images are comparative sections
ight a positively stained cardiac valve. Row 2 displays composite photomerges of H&E
trichrome stained sections from ED 12.5, ED 15.5 and ND 1mice respectively. Structures
pericardium. Scale bar represents 100 μm.
Table 2
Embryo and neonatal wet weights at collection.
WT Npr1−/− p-value
ED 12.5
Males 88.0±8 85.4±12 0.860
Females 88.5±12 70.9±17 0.421
ED 15.5
Males 472.7±31 418.9±15 0.091
Females 387.8±9 432.2±15 0.060
ND 1
Males 1447.5±63 1373.4±42 0.321
Females 1292.8±58 1419.8±36 0.067
All weights are recorded in mg and presented as mean±SEM.
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(pb0.001), but there were no differences in the extent to which blood
pressure increased between genotypes. The observed initial difference
in MAP due to genotype was maintained and remained signiﬁcant
throughout pregnancy (pb0.001).
3.3. Embryonic Npr1−/− and WT heart structure
There were no physical abnormalities evident between Npr1−/−
and WT embryos at any age (Fig. 2A and B.) No cardiac anatomical
abnormalities were apparent in H&E stained serial sections of theFig. 3. Calculated heart size at ED 15.5 and ND 1 (A) and calculated heart size to chest size ra
myocyte nuclei count (C) in Npr1−/−mice compared to WT and parafﬁn embedded H&E sta
Npr1−/− and WT groups respectively. The y axis for both A and B are in arbitrary units det
between the genotypes are indicated by ⁎pb0.05 and ⁎⁎pb0.01. Scale bar represents 100 μthoracic regions of Npr1−/− compared with WT mice at any of the
gestational ages studied (Fig. 2B). Masson's trichrome staining did not
identify aberrant collagen deposition within the hearts of Npr1−/−
mice at any of the gestational ages studied (Fig. 2C).
Both ED 12.5 and 15.5 Npr1−/−mice tended to be lighter than WT
embryos (Table 2), however, the difference was not signiﬁcant. There
was no overall difference in body weight at ND 1 between genotypes.
As an alternative measure embryonic crown-rump lengths (in mm)
were calculated from the digital photos taken at embryo collection (ED
12.5 Npr1−/− 9.33±0.39 vs. WT 9.7±0.12, ED 15.5 Npr1−/− 14.39±
0.22 vs. WT 14.42±0.22), with no signiﬁcant difference in embryo
length at either gestational age (p=0.078 and 0.937 respectively).
Heart dimensions were compared between Npr1−/− andWTmice
from ED 15.5 (at ED 12.5 heart dimensions were not quantiﬁable). An
increase in heart size was apparent from ED 15.5 in Npr1−/− mice
compared to WT (p=0.003, Fig. 3A), while male and female Npr1−/−
hearts at ND 1 were 22% and 29% larger respectively than WT
littermates (p=0.0008). In addition, a signiﬁcant increase in the ratio
between heart size and chest size, an indication of cardiomegaly, was
observed in ND 1 Npr1−/− mice compared to WT (pb0.05, Fig. 3B).
In Npr1−/− mice the increased heart size was due to signiﬁcantly
increased interventricular septal thickness (3.16±0.03 vs. 2.36±0.01
graticule units, p=0.0002) and a trend towards increased left
ventricular free wall thickness (2.22±0.07 vs. 1.82±0.02 graticule
units, p=0.070) compared to WT mice (2.22±0.07 vs. 1.82±0.02
graticule units, p=0.070). There were no signiﬁcant differences intio at ED 15.5 and ND 1 in Npr1−/−mice compared to WT (B), left ventricular free-wall
ined sections from the left ventricular free-wall (D). Black and light grey bars represent
ermined from and eye piece graticule as described in Methods. Signiﬁcant differences
m.
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p=0.611) or thickness of right ventricular free wall (1.84±0.01 vs.
1.73±0.01 units, p=0.179) between genotypes. Furthermore while
there was no signiﬁcant difference in the number of cardiomyocyte
nuclei within the left ventricular free wall at either ED 12.5 and ND 1,
ED 15.5 Npr1−/− mice had signiﬁcantly fewer nuclei than WT mice
(17 nuclei vs. 21 nuclei, p=0.0019, Fig. 3C), indicating cardiac
enlargement resulted from hypertrophy rather than hyperplasia.
3.4. Natriuretic peptide expression during development
As expected, quantitative real-time PCR demonstrated higher
mRNA levels of both the cardiac natriuretic peptides, ANP and BNP, inFig. 4. Gestational expression of ANP mRNA (A), BNP mRNA (B), left ventricular ANP pro
ventricular ANP protein (E) inNpr1−/−mice compared toWT control mice. ^Quantitated gen
RNA), except for ND 1 where ANP expression gene expression is expressed as nanograms of m
red asterisks denote left ventricular lumen. Protein expression represents the accumulation o
software. Black and grey bars represent Npr1−/− and WT groups respectively. Signiﬁcant dNpr1−/− mice compared to WT at all three gestational ages. In
particular ANP message expression was signiﬁcantly increased in
Npr1−/−mice at ED 12.5 (whole embryos) and ND 1 (isolated hearts,
Fig. 4A) when compared to WT. While not signiﬁcant, BNP gene
expression levels tended to be higher in Npr1−/− mice compared to
WT at all three gestational ages (Fig. 4B).
Immunohistochemical analysis showed aggregations of ANP
protein throughout the atria and within the trabecular region of the
cardiac ventricles of Npr1−/− andWTmice during gestation (Fig. 4C).
ANP protein staining was signiﬁcantly greater in both the left atria
(Fig. 4D) and LV (Fig. 4E) of Npr1−/− compared to WT mice at all
three gestational time points. As expected ANP protein expression
within the LVwas signiﬁcantly greater inNpr1−/−mice thanWTmicetein staining (C), and quantitation of staining for left atrial ANP protein (D) and left
e levels are expressed as picograms of message per microgram of total RNA (pg/μg total
essage per microgram of total RNA (ng/μg total RNA). Scale bar represents 100 μm and
f ANP protein measured by immunohistochemistry using MetaMorph™ image analysis
ifferences between the genotypes are indicated by ⁎pb0.05 and †pb0.001.
Table 3
Levels of cardiac gene and protein expression in Npr1−/− mice compared to WT during cardiac development.
ED 12.5 ED 15.5 ND 1
WT Npr1−/− WT Npr1−/− WT Npr1−/−
GATA GATA-4 mRNA 0.000135±0.00002 0.0000987±0.00001 0.000501±0.00007 0.000646±0.00006 0.00979±0.002 0.0046±0.0007⁎
GATA-6 mRNA 0.00438±0.0005 0.00329±0.0004 0.00352±0.002 0.00171±0.0002 0.145±0.02 0.0168±0.02
GATA-4 protein 169.9±8 170.3±8 178.7±9 183.2±10 189.1±10 181.8±13
Mef2 MEF2A mRNA 0.0229±0.002 0.0193±0.003 0.0439±0.006 0.0573±0.007 0.100±0.01 0.117±0.01
MEF2C mRNA 0.00832±0.0007 0.00501±0.0006 0.00424±0.0007 0.0067±0.0007 0.000223±0.00004 0.000235±0.00004
MEF2^ protein 147.9±11 176.5 ±12 157.2±10 140.9±12 163.0±24 102.2±22⁎
SRF mRNA 0.0000543±0.00003 0.00206±0.002 0.000302±0.0001 0.000471±0.0002 0.0328±0.01 0.0164±0.009
protein 208.3±10 209.6±7 171.7±7 171.6±9 184.1±9 187.4±10
All data presented is calculated mean±SEM, where males and females were combined. mRNA levels are absolute amounts of gene expression in pgmessage/μg of total RNA. Protein
expression represents the accumulation of speciﬁc protein measured by immunohistochemical densitometry using MetaMorph™ image analysis software and is expressed as
arbitrary intensity units.
⁎ pb0.05 Npr1−/− compared to age matched WT.
^ Mef2 antibody was a universal antibody detecting Mef2A, Mef2C and Mef2D proteins.
1181N.J.A. Scott et al. / Biochimica et Biophysica Acta 1792 (2009) 1175–1184(193.6±7 in Npr1−/− vs. 124.8±5 in WT, pb0.001) and was
maximally expressed at ED 15.5. There was no signiﬁcant gender
inﬂuence on ANP protein expression in either the atria or ventricles
(p=0.570 and 0.859, respectively). In WT mice, levels of ANP
expression within the left atria increased signiﬁcantly with gesta-
tional age (pb0.001), however, in Npr1−/− mice left atrial ANP
protein levels appeared to peak at ED 15.5.
3.5. Transcription factor expression during development
Gene and protein expression levels of transcription factors
implicated in cardiac development; GATA-4, GATA-6, Mef2A, Mef2C
and SRF, were investigated in Npr1−/−mice compared to WT and are
shown in Table 3. GATA-4 mRNA and Mef2 protein levels were
signiﬁcantly reduced in Npr1−/− mice at ND1, but neither gene or
protein expression of the other transcription factors was altered.
Gestational age signiﬁcantly inﬂuenced gene expression levels
(pb0.001 for all genes except BNP where p=0.008). All transcription
factor gene expression was signiﬁcantly correlated to gestational age
(Pearson's correlation coefﬁcients of r=−0.422, 0.561, 0.665, 0.725
and 0.614, pb0.01 for Mef2A, Mef2C, GATA-4, GATA-6 and SRF
respectively).
3.6. Renin–angiotensin system gene expression during development
Gene expression levels of angiotensinogen, the angiotensin II
type I receptor (AT1R) and the angiotensin converting enzyme
(ACE) were investigated. There was no signiﬁcant difference in
expression levels between genotypes at any stage of development
(Table 4).
3.7. Hypertrophy-related gene expression during development
Expression levels of markers of physiologically derived cardiac
hypertrophy, Akt1, and pathological cardiac hypertrophy, Calcineurin
A, were investigated (Table 4). While both genes were differentially
expressed with gestational age, Akt1 expression was signiﬁcantlyTable 4
Levels of renin–angiotensin system and pro-hypertrophic gene expression in Npr1−/− mice
ED 12.5 ED 15.5
WT Npr1−/− WT
Angiotensinogen 0.00122±0.0005 0.00046±0.0001 0.00421±0
ACE 0.00012±0.0001 0.00011±0.0001 0.00050±0
AT1R 0.00034±0.00004 0.00026±0.0001 0.0612±0
Akt1 0.859±0.1 0.443±0.01⁎ 0.492±0
Calcineurin A 0.207±0.05 0.098±0.03 0.0015±0
All data presented are calculated mean±SEM, where males and females were combined. mreduced in Npr1−/−mice only at ED12.5 compared toWT (p=0.024),
while Calcineurin A expression was signiﬁcantly increased in the
hearts of ND 1 Npr1−/− mice (p=0.031).
3.8. Connexin 43 gene and protein expression in Npr1−/− mice
during development
Cx43 gene and protein expression decreased signiﬁcantly with
gestational age irrespective of Npr1 genotype (Fig. 5A). However at
ND 1 mRNA levels were signiﬁcantly higher in Npr1−/− hearts
compared to WT (p=0.044, Fig. 5A). Additionally, developmental
age, gender and Npr-1 genotype in combination inﬂuenced Cx43 gene
expression (p=0.019).
Cx43 protein is detected in the adult myocardium along the
myocyte margins, with Cx43 positive protein regions forming
aggregations of gap junctions. During cardiac development Cx43
protein was expressed within both the myocardium of the cardiac
atria and ventricles in both Npr1−/− and WT mice (Fig. 5B), but
excluded from the regions of the cardiac cushions and cardiac valves
(Fig. 5B). Maximum Cx43 protein expressionwas evident at ED 12.5 in
both Npr1−/− and WT mice. Cx43 hemi-channel aggregations at the
myocardial cell membrane were also detected in the myocardium
from ED 12.5; however they were more diffuse in localization
compared to the high density of aggregations evident in the hearts
of ND 1 and adult mice.
Cx43 protein expression was signiﬁcantly different between
genotypes dependent on gestational age (p=0.014, Fig. 5C), with
levels of Cx 43 protein signiﬁcantly reduced in the ventricles of
Npr1−/− mice at ED 15.5 (p=0.029).
4. Discussion
In the current study, Npr-1 gene ablation was shown to reduce
gestational survival and contribute to left ventricular hypertrophy
(LVH) in the developing hearts of Npr1−/−mice. Despite the presence
of cardiomyocyte hypertrophy, there was no signiﬁcant change in
gene expression of hypertrophy-related transcription factors. Therecompared to WT during cardiac development.
ND 1
Npr1−/− WT Npr1−/−
.003 0.00225±0.001 0.00161±0.0007 0.00056±0.0003
.0002 0.00060±0.0002 0.00018±0.0001 0.00004±0.00003
.01 0.06265±0.008 0.0351±0.0003 0.0347±0.0004
.02 0.750±0.09 0.0007±0.0002 0.004±0.002
.0008 0.0107±0.005 0.042±0.02 0.165±0.05⁎
RNA levels are absolute amounts of gene expression in pg message/μg of total RNA.
Fig. 5. Gestational expression of Cx43 mRNA (A) and protein (B, C) in Npr1−/− andWT mice. (B) Representative micrographs of Cx43 protein expression in whole hearts of ED 12.5
and left ventricles of ED 15.5 and ND 1 mice. (C) Quantitation of Cx43 protein expression in the left ventricle of Npr1−/− and WT mice. Quantitated gene levels are expressed as
picograms of message per microgram of total RNA (pg/μg total RNA). Protein expression represents the accumulation of Cx43 protein measured by immunohistochemistry using
MetaMorph™ image analysis software. Black and grey bars represent Npr1−/− andWT groups, respectively. Signiﬁcant differences between the genotypes are indicated by ⁎pb0.05.
Scale bar represents 100 μm.
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gestation. The absence of any apparent gross developmental
abnormalities in the whole embryos or apparent defects of cardiac
structure, suggests that the decreased viability of Npr1−/−embryos
may result from a combination of cardiomegaly, increased calci-
neurin A expression and decreased Cx43 protein affecting cardiac
contractility. This is the ﬁrst study to examine cardiac structure, gene
expression and protein expression changes in Npr1−/− mice during
embryonic development.
Npr-1 gene ablation is characterized by incremental increases in
blood pressure relative to the number of disrupted alleles [13], as well
as the development of cardiac hypertrophy and ﬁbrosis in post-natal
life [12]. The ﬁndings from this study suggest that Npr-1 activity is
important in embryonic survival as signiﬁcantly fewer than expected
Npr1−/− embryos survived to birth and subsequently to weaning.
Reduced post-natal survival has been previously reported in an
alternative strain of Npr-1 null mice, where the total number of null
mice at 3 weeks of age was only 70% of that expected [27]. It was
reported that a large proportion of the gestational deaths were
attributable to fetal hydrops. Within our colony, the proportion of
Npr1−/− mice surviving at 4 weeks of age was comparable at 68%.
Furthermore we identiﬁed that the decline in the number of Npr1−/−
mice occurred across a continuum from ED 12.5 until birth, indicating
that Npr1−/− embryos were implanted at a normal rate but a degree
of embryonic lethality was evident at mid/late gestation. Fetal
hydrops was not observed in our colony, nor was there evidence of
cardiac structural abnormalities among the surviving embryos at
collection to account for loss of developmental viability. However,signiﬁcant left ventricular hypertrophy was apparent from ED 15.5
onwards in Npr1−/− mice.
Maternal hypertension has been shown to damage and prema-
turely age the placental vasculature [28] and is also associated with
inter-uterine growth retardation, reduced birth weight and increased
neonatal death [29,30]. In surrogate studies using spontaneously
hypertensive rats Di Nicolantonio et al. have shown that the genetic
identity of the fetus determines the growth rate of both the fetus and
the placenta independent of maternal phenotype [31]. In this study
maternal blood pressure was monitored throughout pregnancy.
While there was a signiﬁcant genotype inﬂuence on blood pressure,
the degree of blood pressure elevation as pregnancy progressed was
not signiﬁcantly different between Npr1+/−, Npr1−/− and WT dams.
Nor were there signiﬁcant differences in embryo body weight
between genotypes at any time point investigated. There was no
indicationmaternal hypertension contributed to the gestational death
or resulted in reduced birth weight of Npr1−/− mice during
development.
Histological examination identiﬁed an increase in heart dimen-
sions and subsequent heart size to chest size ratio due to thickening of
the left heart structures, namely the LV free-wall and IVS, in Npr1−/−
mice from ED 15.5. Previously Kuhn et al. have shown Npr-1 null mice
exhibit cardiomyocyte enlargement at both 4 and 12 months of age
[15]. Leu et al. have shown that during the ﬁrst four post-natal days
the volume of cardiomyocytes remains constant despite a concom-
itant increase in cardiac mass, indicating that normal cardiac growth
during this developmental phase is due to cell division [32]. In the
current study the decreased nuclei number suggests the increase in
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enlargement of the myocardial cells (hypertrophy), rather than
through increased cell numbers (hyperplasia) in the left ventricle.
Several studies using both experimental manipulation and
genetic models have explored the gene expression changes
associated with pathological cardiac hypertrophy [14,33]. These
studies and our data strongly suggest that ANP-mediated Npr-1
signaling has a direct inhibitory effect on cardiac hypertrophy.
Horsthuis et al. have shown that distinct regulatory sequences and
divergent regulatory pathways control fetal ANP expression and the
reactivation of ventricular ANP expression during cardiac disease
[34]. Despite the increased levels of natriuretic peptide gene and
protein expression, there was no detected increase in gene
expression of the hypertrophy-related, cardiac transcription factors;
Mef2A, Mef2C, GATA-4, GATA-6 and SRF or genes of the renin–
angiotensin system. This contrasts with adult Npr1−/− mice, in
which we previously reported cardiac hypertrophy was correlated
to increased expression of both the GATA-4 and Mef2C genes in
aged animals [23]. Interestingly our observation of unaltered RAS
gene expression in embryos contrasts with a study by Li et al. [35]
where cardiac hypertrophy and ﬁbrosis in adult Npr1−/− mice was
ascribed to augmented cardiac AT1R signaling. This further
illustrates differential role of natriuretic peptide signaling in the
developing and mature cardiovascular systems. In the absence of
up-regulation of traditional transcriptional markers of pathological
cardiac hypertrophy we investigated the expression of Atk1, a
down-stream effector of the phosphoinositol-3 kinase p110α
subunit (PI3K-P110α), recently implicated as key component of
physiological cardiac hypertrophy [36–38]. Contrary to our expecta-
tions signiﬁcant down-regulation of expression was observed at ED
12.5. Interestingly, Calcineurin A expression increased in Npr1−/−
mice from ED 15.5 (not signiﬁcant) culminating in signiﬁcantly
elevated expression at ND 1 once cardiomyocyte hypertrophy is
observed. These result complement our previous data where
calcium/calmodulin signaling was implicated in the early establish-
ment of cardiac hypertrophy in young Npr1−/− mice [23].
Cx43, like the natriuretic peptides, is a marker of myocardial cell
development during embryogenesis [7]. In the heart, Cx protein-
derived gap junctions provide the pathway for intercellular current
ﬂow, enabling coordinated action potential propagation and contrac-
tion. In adult ventricular muscle, cell-to-cell coupling is formed
predominantly by Cx43 channels. Deranged expression and organi-
zation of Cx43 gap junctions in the ventricle have been demonstrated
in a variety of cardiovascular pathologies, including hypertrophy [39].
Cardiomyocyte-restricted deletion of Cx43 has been shown to result
in increased gestational attrition of null mice from ED 13.5 through to
post-natal day 6 in the absence of major cardiac structural
malformations [40]. Dysregulation of Cx43 activity has been associ-
ated with impaired electrical action of the heart, namely an increased
prevalence of tachyarrhythmias [41,42], such impaired cardiac
conduction might account for the observed gestation deaths in
Npr1−/− mice, particularly the sporadic rate of deaths occurring
along a developmental continuum.
This study has demonstrated that during embryonic development
of Npr1−/− mice, there is progressive LVH from ED 15.5, but no
concomitant up-regulation of hypertrophy-associated, transcription
factor genes or components of the renin–angiotensin system.
However increased ANP expression during embryonic development
was associated with reduced expression of both Cx43 and SRF genes
in Npr1−/− mice. While the morphological cardiac enlargement in
embryonic and adult Npr1−/−mice is similar, the different molecular
characteristics of LVH evident in Npr1−/− mice from ED 15.5
compared to adult Npr1−/−mice indicates that the role of natriuretic
peptide signaling in cardiac development is distinct from that
traditionally attributed to either pathological or physiological cardiac
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